A very low HR in OS is indeed a tough task for a cancer drug; however, some cancer drugs have been approved based on a (non-OS) primary endpoint with HR<0.4.
Let's make this a quiz!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”